Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Pricing & Reimbursement
|
Regulation
|
Healthcare Policy
|
Pharmacovigilance
|
Intellectual Property
|
Policy & Regulation - Pricing & Reimbursement
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
Pharma firms reject Greece's new drug prices
26 August 2010
Many pharmaceutical firms are expected to make objections to some of the new drug prices that were announced by the Greek government's pricing committee last week. Novartis and GlaxoSmithKline, two of the top five players in country in sales terms, ...
FDA hands refusal to file letter to EpiCept for lead leukaemia product
25 August 2010
EpiCept has received a rare refusal to file letter from the US FDA for its NDA for its lead product, Ceplene (histamine dihydrochloride), which it was intending to be a maintenance treatment for patients with acute myeloid leukaemia (AML) in their ...
NICE rejects Roche's Avastin for metastatic colorectal cancer, again
24 August 2010
NICE, the National Institute of health and Clinical Excellence in England and Wales, has again rejected Roche's Avastin (bevacizumab) for metastatic colorectal cancer. An amended patient access scheme submitted by the company failed to convince the ...
FDA panels vote against Jazz bid to sell sodium oxybate for fibromyalgia
23 August 2010
A joint meeting on 20 August of two US FDA advisory committees put major roadblocks in the way of Jazz Pharmaceuticals' new drug application (NDA) to sell sodium oxybate as a treatment for fibromyalgia. The panel of outside experts on arthritis ...
Indian firms see red over fresh attempts to tweak IPR laws
20 August 2010
Indian pharmaceutical firms are protesting against what they claim are attempts by multinational companies to influence and tweak critical aspects of India's intellectual property rights (IPR) legislation. The Indian industry's concern comes ...
 
2010 Scrip 100 - Mixed fortunes on the R&D front
23 August 2010
Continued problems with anti-obesity drugs, more measures designed to improve R&D efficiency, and the approval of first-in-class therapeutics such as Amgen's Prolia and Dendreon's Provenge: the first ...
Liver cancer becomes more preventable and treatable
12 August 2010
New drugs to treat viral hepatitis infection, coupled with renewed interest from companies in developing therapies to treat liver cancer following Nexavar's approval, have improved prospects for both ...
2010 Scrip 100 - Changes pharma can believe in?
23 August 2010
Ian Schofield picks some of the most significant developments in the health policy and regulation circles in the first half of 2010 and explains their likely impacts on pharma. Barack Obama signed ...
 
Interview: Croatia's state insurer changes its role to raise efficiency
19 July 2010
Croatia's HZZO main responsibilities include setting drug prices, selecting reimbursable products and reimbursement. The institute uses France, Italy and Slovenia as reference countries for setting ...
Connexios: Harnessing the Indian cost advantage in network biology
01 June 2010
Imagine if a start-up company could afford to hire enough high-calibre scientists to spend years creating a detailed map of a broad and complex pathology like metabolic disease, incorporating large ...
GE Healthcare aims to end unpredictability in early drug research
Better consistency of the cells used in early-stage drug research could save R&D departments millions of dollars and a lot of wasted time and effort. At GE Healthcare, the commercialisation of ...
 
Value-based pricing: Who should set drug prices in the UK?
11 August 2010
While the UK's NHS and pharma sector ponder who may end up negotiating drug prices in light of a new white paper, health economists Stuart Carroll, Neil Hawkins and David A Scott contemplate four options which keep NICE very much in the picture ...
Value-based pricing for drugs: is the NHS willing to pay?
20 July 2010
Those civil servants who mill around Whitehall are quietly working on what may encompass a whole new pricing system for medicines in England following the publication of the white paper on the National Health Service (NHS) last week. The new UK ...
AstraZeneca judgement changes the rules for dominant companies
07 July 2010
On 1 July 2010 the EU General Court handed down its judgement in the long-running saga of AstraZeneca's proton pump inhibitor anti-ulcer product Losec (omeprazole). Although dealing with events that happened almost two decades ago, the case – ...
 
Decision models for assessing the cost effectiveness of drug-eluting stents
01 June 2005
Percutaneous coronary intervention is an increasingly common treatment for many people with coronary disease. Randomised trials using antiproliferative, drug-eluting stents (DES) have shown important reductions in the need for repeat procedures ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm